Original ArticleCardiomyopathy in neurological disorders
Introduction
Cardiomyopathies (CMPs) are generally characterised by abnormal structure, dimension, or function of the left or right ventricular myocardium in the absence of arterial hypertension, coronary heart disease, valve abnormalities, or congenital heart disease [1]. CMPs may be hereditary or acquired and either confined to the heart or may represent cardiac involvement in systemic disease. Diagnosis of CMP relies on clinical, electrocardiographic, echocardiographic, coronary angiographic, or genetic findings. Complications of CMPs may include neurological disease and neurological disease may be accompanied by CMP. This review aims at summarising and discussing recent findings concerning the neurological implications in CMPs.
Section snippets
Classification of CMPs
There is no binding classification of CMPs but the frequently used classification of the American Heart Association classifies CMPs as primary (solely or predominantly confined to heart muscle), secondary [those showing pathological myocardial involvement as part of a neuromuscular disorder (NMD)] and those in which cardiomyopathy is the first/predominant manifestation of a NMD [2]. The European Society of Cardiology, on the contrary, differentiates according to the etiology between primary
Neurological disease and CMPs
CMPs may be related to neurological disease twofold. CMPs may either secondarily cause neurological disease or may represent the cardiac manifestation of an exclusively or predominantly neurological disease.
Definition and diagnostic criteria
HCM is present if there is left ventricular myocardial thickening >15 mm, with or without normal systolic function, in the absence of any other disease producing wall thickening (Fig. 1). HCM may be non-obstructive or obstructive (Table 2). Hypertrophy of the left ventricular myocardium may be symmetric or asymmetric. Asymmetric myocardial thickening frequently affects the interventricular septum, the mid-ventricular myocardium (MVHC) or the outflow tract. If myocardial thickening predominantly
Definition and diagnostic criteria
DCM is diagnosed if there is dilation of the left ventricle (LVEDD >57 mm), and systolic dysfunction (FS <25%) in the absence of abnormal loading conditions or coronary artery disease sufficient to cause global systolic impairment (Fig. 2). In some patients DCM may be accompanied by myocardial thickening.
Clinical presentation and treatment
Patients with DCM frequently develop heart failure or arrhythmias. Pharmacotherapy consists of medication with ACE-inhibitors, beta-blockers, or diuretics. In cases with systolic dysfunction (EF
Definition and diagnostic criteria
RCM is a rare form of CMP and diagnosed echocardiographically if there is dilation of the right and left atrium, a restrictive filling pattern (deceleration time <150 ms on transmitral flow), presence of normal or reduced diastolic and systolic ventricular volumes, normal LV wall thickness, and normal systolic function. RCM is either idiopathic or a manifestation of cardiac involvement in systemic disease, predominantly NMDs (Table 5) [121].
Clinical presentation and treatment
Patients with RCM may be asymptomatic but more
Definition and diagnostic criteria
ARVC, also known as arrhythmogenic right ventricular dysplasia or arrhythmogenic right ventricular dysplasia/CMP, is an inherited or acquired, non-ischemic CMP, which primarily involves the right ventricle affecting children and young adults. It is now well recognized that also the left ventricle may be affected. ARVC is characterized by structural abnormalities of the right ventricular myocardium, hypokinetic areas involving the free wall of the right ventricle, and progressive fibrofatty
Definition and diagnostic criteria
LVHT is characterised by hypertrabeculation of the left ventricular myocardium apically to the papillary muscles. The cause of LVHT is unknown but it is frequently associated with genetic disease and chromosomal abnormalities. LVHT is preferentially diagnosed on echocardiography. Several echocardiographic definitions have been proposed but none turned out to be binding so far. According to one frequently applied definition LVHT is present on echocardiography if there are more than three
Definition and diagnostic criteria
Takotsubo-CMP is defined as reversible left ventricular systolic dysfunction in the absence of coronary heart disease, triggered by stress [186]. It is echocardiographically characterized by left-ventricular ballooning, wall motion abnormalities, and severely reduced systolic function. Electrocardiogram (ECG) and clinical presentation mimic acute coronary syndrome or myocardial infarction. Blood tests may reveal cardiac enzyme-release. Typically, echocardiographic and ECG abnormalities resolve
Clinical implications
The presented data imply a number of clinical consequences. First, the risk of neurological disease from CMP is poorly investigated and requires a multicenter approach to assess if the stroke rate is truly increased in patients with CMP, which patients with CMP carry an increased stroke risk, or which are the optimal strategies to prevent stroke from CMP. Second, patients with primary and secondary NMD need to be obligatorily investigated for cardiac disease, including CMP. Cardiac
Conclusions
Patients with CMPs require special attention by the cardiologist and neurologist. CMPs may cause central nervous system disease, which can be prevented if adequate measures are taken in time. Additionally, neurological disease in particular NMDs may manifest with CMPs, why all these patients should be seen by the cardiologist as soon as the neurological diagnosis is established. Patients with cardiac involvement from a NMD require regular cardiac follow-ups not to miss the point when essential
References (224)
Guidelines for the diagnosis and management of hypertrophic cardiomyopathy
Heart Lung Circ
(2011)- et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J Am Coll Cardiol
(2008) - et al.
Tissue Doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy
J Am Soc Echocardiogr
(2011) - et al.
Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope
Am J Cardiol
(2002) - et al.
Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching
J Am Soc Echocardiogr
(2011) - et al.
Facioscapulohumeral muscular dystrophy presenting with hypertrophic cardiomyopathy: a case study
Neuromuscul Disord
(2009) - et al.
Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy
Am J Hum Genet
(2009) - et al.
Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy
Biochem Biophys Res Commun
(2004) - et al.
Novel splice site mutation in the caveolin-3 gene leading to autosomal recessive limb girdle muscular dystrophy
Neuromuscul Disord
(2006) - et al.
Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation
Neuromuscul Disord
(2006)
Nemaline myopathy and non-fatal hypertrophic cardiomyopathy caused by a novel ACTA1 E239K mutation
J Neurol Sci
Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation
Neuromuscul Disord
Physical therapy management of Pompe disease
Genet Med
Myoadenylate deaminase deficiency, hypertrophic cardiomyopathy and gigantism syndrome
Pediatr Neurol
Deficiency of the mitochondrial phosphate carrier presenting as myopathy and cardiomyopathy in a family with three affected children
Neuromuscul Disord
Hypertrophic cardiomyopathy in Friedreich's ataxia
Int J Cardiol
Neurocardiogenic mechanisms of unexplained syncope in idiopathic dilated cardiomyopathy
Am J Cardiol
The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy
Neuromuscul Disord
A mutation in the X-linked Emery-Dreifuss muscular dystrophy gene in a patient affected with conduction cardiomyopathy
Neuromuscul Disord
Prevalent cardiac phenotype resulting in heart transplantation in a novel LMNA gene duplication
Neuromuscul Disord
Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene
Neuromuscul Disord
LGMD2E patients risk developing dilated cardiomyopathy
Neuromuscul Disord
Phenotypic aspects of FKRP-linked muscular dystrophy type 2I in a series of eleven patients
Rev Neurol (Paris)
Dilated cardiomyopathy may be an early sign of the C826A Fukutin-related protein mutation
Neuromuscul Disord
Centronuclear myopathy and cardiomyopathy requiring heart transplant
Brain Dev
Natural history of Danon disease
Genet Med
Distal lipid storage myopathy due to PNPLA2 mutation
Neuromuscul Disord
In situ hybridization of mitochondrial DNA in the heart of a patient with Kearns-Sayre syndrome and dilatative cardiomyopathy
Hum Pathol
Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome
Biochem Biophys Res Commun
Oculopharyngodistal myopathy — a possible association with cardiomyopathy
Neuromuscul Disord
Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Eur Heart J
Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention
Circulation
Primary myopathies and the heart
Scand Cardiovasc J
Left atrial function and left atrial appendage flow velocity in hypertrophic cardiomyopathy: comparison of patients with and without paroxysmal atrial fibrillation
J Cardiol
Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
BMC Med Genet
Atypical phenotype of Fabry disease. Evidence of a new mutation
Presse Med
Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy
Circ J
Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy
Arq Bras Cardiol
Hypertrophic cardiomyopathy: a rare cause of vascular dementia. A case report
Tunis Med
Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up
Eur Heart J
Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy
Am J Cardiol
Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope
Clin Med Res
Clinical features and outcome of patients with apical hypertrophic cardiomyopathy in Taiwan
Cardiology
Two cases of cerebral embolism caused by apical thrombi in midventricular obstructive cardiomyopathy
Intern Med
Ischemic cerebrovascular complications and risk factors in idiopathic hypertrophic subaortic stenosis
Stroke
Idiopathic hypertrophic subaortic stenosis and cerebral ischemia
Stroke
Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis
Stroke
Clinical and angiographic characteristics of mid-ventricular hypertrophic obstructive cardiomyopathy
Zhonghua Xin Xue Guan Bing Za Zhi
Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction
Pediatr Cardiol
Cardiac involvement in facioscapulohumeral muscular dystrophy
Cardiology
Cited by (32)
Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study
2022, eClinicalMedicineCitation Excerpt :Generally, hypertrophic cardiomyopathy is a less common type of cardiac abnormalities associated with neuromuscular disorders (NMDs).29 The NMDs most commonly associated with HCM include Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, myofibrillar myopathy, metabolic myopathy and Friedreich's ataxia (FRDA).30 In the USA cohort, 64 patients (7.5%) had neuromuscular disorders, and 56 patients of them were FRDA according to their supplemental data.11
Neurologic Manifestations of Acquired Cardiac Disease and Arrhythmias
2021, Aminoff’s Neurology and General MedicineNeurological complications of cardiomyopathies
2021, Handbook of Clinical NeurologyCitation Excerpt :Heart involvement in neuromuscular diseases is discussed further below. Although the relationship between the cardiomyopathies and neurological diseases is usually thought to be bidirectional, such relationship is in fact more complex (Finsterer et al., 2013; Finsterer and Wahbi, 2014) (Fig. 9.3). Severe acute neurological events, such as status epilepticus and aneurysmal subarachnoid hemorrhage, may result in an acute cardiomyopathy like of Takotsubo cardiomyopathy.
Diagnostic Pathology: Cardiovascular
2018, Diagnostic Pathology: CardiovascularPathophysiology of Cardiomyopathies
2017, Fetal and Neonatal Physiology, 2-Volume SetRestrictive Cardiomyopathy Associated With Skeletal Myopathies
2017, Cardioskeletal Myopathies in Children and Young Adults